Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights".
Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer, Leticia Alves da Silva, John L. McKee, Tamara Hell, Giulia Cicalese, Marion Holy, Fatemeh Kooti, Kathrin Jäntsch, Ricarda Baron, Naomi Shacham, Bruna Cuccurazzu, Adam L. Halberstadt, John D. Mccorvy, Thomas Stockner, Markus R Meyer, Raúl López‐arnau, Matthias Grill, Harald H. Sitte
ACS Chem Neurosci March 4, 2026 correction DOI: 10.1021/acschemneuro.6c00136 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Correction |
|---|---|
| Topics | MDMA |
| Key points | Only the 10 mg/kg dose of SDA, not SDMA, significantly increased thigmotaxis in rats. |
Abstract
Correction 1: Table 1.The analyses were conducted using the correct data, and all results, interpretations, and conclusions in the paper remain fully accurate.The issue is limited to the presentation of values in the table.Correction 2: p 4733, second paragraph, 1 st sentence.Thigmotaxis was evaluated to assess potential anxiety-like effects induced by the compounds.When comparing the tested doses of SDA and SDMA (2.5, 10, and 25 mg/kg) with saline (Figure 5B and 5E, respectively), a significant increase in thigmotaxis, reflected by reduced time spent in the center of the arena, was observed only for SDA at 10 mg/kg.